Amneal to Report First Quarter 2019 Results on May 9, 2019

April 8, 2019

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL: https://event.on24.com/wcc/r/1956483/BE86212DB4A693962AB0C83F08260E1C

To access the call through a conference line, dial (866) 652-5200 (in the U.S.) and (412) 317-6060 (international callers).

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (877) 344-7529 (in the U.S.) and (412) 317-0088 (international callers). The access code for the replay is 10130469.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,000 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal is one of the largest generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders, endocrinology and parasitic infections. For more information, visit www.amneal.com.

Mark Donohue
Investor Relations and Corporate Communications
(908) 409-6718
www.amneal.com

Source: Amneal Pharmaceuticals, Inc.